Eva Lin
Impact in
Papers in
-
- Melanoma and MAPK Pathways 8
- PI3K/AKT/mTOR signaling in cancer 5
- Ubiquitin and proteasome pathways 4
- Protein Degradation and Inhibitors 3
- Protein Kinase Regulation and GTPase Signaling 3
-
- Hippo pathway signaling and YAP/TAZ 4
- Co-authors
- Ruth G. Perez (4 shared papers)Michael J. Zigmond (4 shared papers)Fengli Guo (2 shared papers)Jack C. Waymire (2 shared papers)Jeff Settleman (5 shared papers)Richard M. Neve (4 shared papers)Hartmut Koeppen (2 shared papers)John G. Moffat (3 shared papers)
- Journals
- Nature (4 papers)Nature Communications (4 papers)Clinical Cancer Research (4 papers)Journal of the American Chemical Society (2 papers)Molecular Cancer Research (2 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Eva Lin
43 papers receiving 4.3k citations
Eva Lin's Hit Papers
Peers
Comparison fields: 5 of 124
- Neurology 922
- Oncology 1.2k
- Cellular and Molecular Neuroscience 650
- Molecular Biology 2.1k
- Cancer Research 418
Countries citing papers authored by Eva Lin
This map shows the geographic impact of Eva Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Lin more than expected).
Fields of papers citing papers by Eva Lin
This network shows the impact of papers produced by Eva Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Lin. The network helps show where Eva Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Eva Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Hit paper breakdown → | 2012 | 969 |
| 2 | 2002 | 545 | |
| 3 | 2002 | 528 | |
| 4 | 2017 | 278 | |
| 5 | 2009 | 256 | |
| 6 | 2016 | 219 | |
| 7 | 2008 | 200 | |
| 8 | An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance Hit paper breakdown → | 2023 | 142 |
| 9 | 2014 | 126 | |
| 10 | 2014 | 121 | |
| 11 | 2022 | 112 | |
| 12 | 2004 | 99 | |
| 13 | 2021 | 97 | |
| 14 | 2003 | 74 | |
| 15 | 2017 | 72 | |
| 16 | 2009 | 61 | |
| 17 | 2018 | 60 | |
| 18 | 2007 | 56 | |
| 19 | 2018 | 55 | |
| 20 | 2001 | 49 |
About Eva Lin
Eva Lin is a scholar working on Molecular Biology, Cell Biology, Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 43 papers that have together received 4.5k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (8 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer Genomics and Diagnostics (4 papers), Cancer Mechanisms and Therapy (4 papers), Ubiquitin and proteasome pathways (4 papers), Hippo pathway signaling and YAP/TAZ (4 papers), Protein Degradation and Inhibitors (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). The work is most often cited by research in Neurology (922 citations), Oncology (1.2k citations), Cellular and Molecular Neuroscience (650 citations), Molecular Biology (2.1k citations) and Cancer Research (418 citations). Eva Lin has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Ruth G. Perez, Michael J. Zigmond, Fengli Guo, Jack C. Waymire, Jeff Settleman, Richard M. Neve, Hartmut Koeppen, John G. Moffat, Mark A. Merchant and Yibing Yan. Their work appears in journals such as Nature, Nature Communications, Clinical Cancer Research, Journal of the American Chemical Society and Molecular Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.